Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 255
- Registration Number
- NCT05624268
- Locations
- 🇺🇸
University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States
🇺🇸ProScience Research Group, Culver City, California, United States
🇺🇸Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
PET Synaptogenesis After Psilocybin In DEpression Recovery
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT05601648
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effect of SSRIs on Response to Psilocybin Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Cybin Therapeutics Inc.
- Registration Number
- NCT05594667
- Locations
- 🇨🇦
Centre for Neurology Studies x Upstream, Abbotsford, British Columbia, Canada
Consciousness, Psilocybin, and Well-Being
- Conditions
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 23
- Registration Number
- NCT05592379
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT05562973
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT05557643
- Locations
- 🇺🇸
Huntsman Mental Health Institute, Salt Lake City, Utah, United States
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 15
- Registration Number
- NCT05554094
- Locations
- 🇺🇸
Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center, Columbus, Ohio, United States
Effects of Psilocybin in Obsessive Compulsive Disorder
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT05546658
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT05548075
- Locations
- 🇬🇧
Imperial College London, London, United Kingdom
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 24
- Registration Number
- NCT05523401
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.